Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Purple Biotech Ltd ADR (NQ: PPBT ) 0.3977 UNCHANGED Streaming Delayed Price Updated: 3:57 PM EDT, Aug 21, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Purple Biotech Ltd ADR < Previous 1 2 3 Next > PPBT Stock Earnings: Purple Biotech Beats EPS for Q2 2024 August 16, 2024 PPBT stock results show that Purple Biotech beat analyst estimates for earnings per share the second quarter of 2024. Via InvestorPlace Purple Biotech Receives Extension to Regain Compliance with the Nasdaq’s Minimum Bid Price Rule July 25, 2024 From Purple Biotech Ltd. Via GlobeNewswire Purple Biotech Announces Closing of Exercise of Warrants for $2 Million Gross Proceeds July 02, 2024 From Purple Biotech Ltd. Via GlobeNewswire Why Purple Biotech (PPBT) Shares Are Trading Lower July 01, 2024 Purple Biotech shares are trading lower by 11.5% during Monday's session. The company announced the exercise of warrants for $2 million gross proceeds. Via Benzinga Purple Biotech: Q3 Earnings Insights November 21, 2023 Via Benzinga Purple Biotech to Host Virtual KOL Event to Discuss Positive Interim Results from Phase 2 Pancreatic Cancer Study with CM24 on July 11, 2024 July 10, 2024 From Purple Biotech Ltd. Via GlobeNewswire Purple Biotech Announces Exercise of Warrants for $2 Million Gross Proceeds July 01, 2024 From Purple Biotech Ltd. Via GlobeNewswire Purple Biotech Reports Additional Positive Interim Results from its Randomized Phase 2 Pancreatic Cancer Study with CM24 Regarding a Potential Predictive Biomarker for Overall Survival Benefit June 27, 2024 From Purple Biotech Ltd. Via GlobeNewswire 12 Health Care Stocks Moving In Tuesday's Pre-Market Session June 11, 2024 Via Benzinga 12 Health Care Stocks Moving In Monday's After-Market Session June 10, 2024 Via Benzinga Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and other Efficacy Endpoints in Pancreatic Cancer June 01, 2024 From Purple Biotech Ltd. Via GlobeNewswire 12 Health Care Stocks Moving In Friday's Intraday Session May 31, 2024 Via Benzinga 12 Health Care Stocks Moving In Thursday's After-Market Session May 23, 2024 Via Benzinga 12 Health Care Stocks Moving In Thursday's Intraday Session May 23, 2024 Via Benzinga PPBT Stock Earnings: Purple Biotech Beats EPS for Q1 2024 May 21, 2024 PPBT stock results show that Purple Biotech beat analyst estimates for earnings per share the first quarter of 2024. Via InvestorPlace 12 Health Care Stocks Moving In Friday's After-Market Session May 10, 2024 Via Benzinga Purple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting April 25, 2024 From Purple Biotech Ltd. Via GlobeNewswire 12 Health Care Stocks Moving In Monday's After-Market Session April 22, 2024 Via Benzinga Purple Biotech to Present New Data On its Oncology Drug NT219 at AACR 2024 March 28, 2024 From Purple Biotech Ltd. Via GlobeNewswire Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technology March 14, 2024 From Purple Biotech Ltd. Via GlobeNewswire PPBT Stock Earnings: Purple Biotech Meets EPS for Q4 2023 March 05, 2024 PPBT stock results show that Purple Biotech met analyst estimates for earnings per share the fourth quarter of 2023. Via InvestorPlace Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024 February 27, 2024 From Purple Biotech Ltd. Via GlobeNewswire Purple Biotech Convenes a Head & Neck Cancer Scientific Advisory Board in Preparation for NT219 Phase 2 Trial February 13, 2024 From Purple Biotech Ltd. Via GlobeNewswire Purple Biotech Reaches Recommended Phase 2 Dose for NT219 February 01, 2024 From Purple Biotech Ltd. Via GlobeNewswire 12 Health Care Stocks Moving In Wednesday's After-Market Session January 10, 2024 Via Benzinga Purple Biotech Appoints Dr. Yael Margolin to its Board of Directors December 20, 2023 From Purple Biotech Ltd. Via GlobeNewswire Purple Biotech Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trial December 14, 2023 From Purple Biotech Ltd. Via GlobeNewswire 12 Health Care Stocks Moving In Monday's Pre-Market Session December 11, 2023 Via Benzinga Why Green Giant Shares Are Trading Lower By Around 37%; Here Are 20 Stocks Moving Premarket December 11, 2023 Shares of Green Giant Inc. (NASDAQ: GGE) fell sharply in pre-market trading after announcing a proposed public offering. Green Giant shares dipped 37.1% to $0.1599 in pre-market trading. Here are some... Via Benzinga Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday December 11, 2023 It's time to start the trading week with a look at the biggest pre-market stock movers worth watching for Monday morning! Via InvestorPlace < Previous 1 2 3 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.